These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25832882)

  • 1. Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    Future Oncol; 2015; 11(8):1275-90. PubMed ID: 25832882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.
    Lu Y; Zhao Z; Wang J; Lv W; Lu L; Fu W; Li W
    Medicine (Baltimore); 2018 Oct; 97(41):e12784. PubMed ID: 30313101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
    Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J
    Future Oncol; 2017 Mar; 13(7):615-624. PubMed ID: 27802780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
    Claringbold PG; Price RA; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
    Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
    Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.
    Abdel-Rahman O; Fouad M
    Tumour Biol; 2015 Feb; 36(2):467-78. PubMed ID: 25596701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
    Chatzellis E; Angelousi A; Daskalakis K; Tsoli M; Alexandraki KI; Wachuła E; Meirovitz A; Maimon O; Grozinsky-Glasberg S; Gross D; Kos-Kudła B; Koumarianou A; Kaltsas G
    Neuroendocrinology; 2019; 109(4):333-345. PubMed ID: 31167197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
    Kulke MH; Stuart K; Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Vincitore M; Michelini A; Fuchs CS
    J Clin Oncol; 2006 Jan; 24(3):401-6. PubMed ID: 16421420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
    Al-Toubah T; Morse B; Strosberg J
    Oncologist; 2020 Jan; 25(1):e48-e52. PubMed ID: 31455747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
    Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
    Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
    Chan JA; Stuart K; Earle CC; Clark JW; Bhargava P; Miksad R; Blaszkowsky L; Enzinger PC; Meyerhardt JA; Zheng H; Fuchs CS; Kulke MH
    J Clin Oncol; 2012 Aug; 30(24):2963-8. PubMed ID: 22778320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
    Koumarianou A; Antoniou S; Kanakis G; Economopoulos N; Rontogianni D; Ntavatzikos A; Tsavaris N; Pectasides D; Dimitriadis G; Kaltsas G
    Endocr Relat Cancer; 2012 Feb; 19(1):L1-4. PubMed ID: 22232542
    [No Abstract]   [Full Text] [Related]  

  • 15. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
    Fine RL; Gulati AP; Krantz BA; Moss RA; Schreibman S; Tsushima DA; Mowatt KB; Dinnen RD; Mao Y; Stevens PD; Schrope B; Allendorf J; Lee JA; Sherman WH; Chabot JA
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):663-70. PubMed ID: 23370660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
    Claringbold PG; Turner JH
    Neuroendocrinology; 2016; 103(5):432-9. PubMed ID: 26065489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
    Abbasi S; Kashashna A; Albaba H
    Pancreas; 2014 Nov; 43(8):1303-5. PubMed ID: 25036906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
    Koumarianou A; Kaltsas G; Kulke MH; Oberg K; Strosberg JR; Spada F; Galdy S; Barberis M; Fumagalli C; Berruti A; Fazio N
    Neuroendocrinology; 2015; 101(4):274-88. PubMed ID: 25924937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab plus temozolomide: a novel treatment option for advanced neuroendocrine tumors?
    Koumarianou A; Kaltsas G
    J Clin Oncol; 2013 Mar; 31(7):975-6. PubMed ID: 23358970
    [No Abstract]   [Full Text] [Related]  

  • 20. Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update.
    Bajetta E; Catena L; Pusceddu S; Spada F; Iannacone C; Sarno I; Di Menna G; Dottorini L; Marte AM
    Neuroendocrinology; 2018; 106(4):307-311. PubMed ID: 28743120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.